Abstract
Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that has recently become available for use in patients with relapsing or refractory acute myeloid leukemia. Reversible hepatotoxicity is common after administration. We describe the first report of hepatic veno-occlusive disease (HVOD) developing after Mylotarg infusion in a patient who underwent hematopoietic stem cell transplantation 8 months earlier. Certain antineoplastic agents have been implicated as a cause of HVOD, but the disease is most commonly seen within 30 days after hematopoietic stem cell transplantation. The possible association between Mylotarg infusion and HVOD is discussed. Bone Marrow Transplantation (2001) 28, 895–897.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sievers EL, Applebaum FR, Spielberger RT et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678–3684
Sievers EL, Larson RA, Estey E et al. Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse Blood 1998 92 (Suppl. 1): 613a (Abstr.)
Richardson P, Guinan E . The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches Br J Haematol 1999 107: 485–493
Feldman M, Sleisenger MH, Scharschmidt BF (eds). Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management, 6th edn WB Saunders Company: Philadelphia 1998
Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 1995 85: 3005–3020
Appelbaum FR . Antibody-targeted therapy for myeloid leukemia Semin Hematol 1999 36 (Suppl. 6): 2–8
Anon Celltech/Wyeth to file CMA 676NDA in third quarter FDC Reports: The Pink Sheet 1999 61: 18–19
Sato Y, Asada Y, Hara S et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation Histopathology 1999 34: 66–70
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tack, D., Letendre, L., Kamath, P. et al. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant 28, 895–897 (2001). https://doi.org/10.1038/sj.bmt.1703242
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703242
- Springer Nature Limited
Keywords
This article is cited by
-
Prodrugs as drug delivery system in oncology
Cancer Chemotherapy and Pharmacology (2019)
-
Antibody–Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned
Clinical Pharmacokinetics (2018)
-
A Murine Model of Hepatic Veno-occlusive Disease Induced by Allogeneic Hematopoietic Stem Cell Transplantation
Cell Biochemistry and Biophysics (2013)
-
Hepatic Sinusoidal Obstruction Syndrome in a child after chemotherapy for medulloblastoma
Journal of Neuro-Oncology (2010)
-
Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention
Bone Marrow Transplantation (2004)